At its meeting on 2 January 2023, the Transparency Council adopted opinion No. 3/2023 on the legitimacy of granting reimbursement approvals for the medicine Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate) for the indication: hypophosphatemic rickets.